Quynh-Thu Le

Molecular Biology · 2006–2019

A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

Whom Quynh-Thu Le trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Nikolaus Rajewsky (in Cancer Research)

Who trusts Quynh-Thu Le

  1. Pengfei Lu (in Molecular Biology)
  2. Valerie M. Weaver (in Molecular Biology)
  3. G. Semenza (in Cancer Research)
  4. Zena Werb (in Molecular Biology)

Papers from Quynh-Thu Le's perspective

Ordered by how strongly the researchers Quynh-Thu Le trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. (The Lancet Oncology)
  2. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
  3. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
  4. Widespread changes in protein synthesis induced by microRNAs (Nature)
  5. Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate (Clinical Cancer Research)
  6. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 (Clinical Cancer Research)
  7. Lysyl oxidase is essential for hypoxia-induced metastasis (Nature)
  8. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (The Lancet Oncology)
  9. The impact of microRNAs on protein output (Nature)
  10. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. (The Lancet)

Their papers